Canaccord raised the firm’s price target on Neurocrine to $167 from $164 and keeps a Buy rating on the shares. The firm said they reported sold Q2 results and management raised its 2024 sales outlook and is also investing to drive additional growth.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $180 from $157 at Baird
- Neurocrine price target raised to $180 from $169 at Barclays
- Neurocrine price target raised to $190 from $160 at H.C. Wainwright
- Neurocrine raises FY24 INGREZZA net product sales view to $2.25B-$2.3B
- Neurocrine reports Q2 adjusted EPS $1.63, consensus $1.03